Aqueous Humor Flow in Normal Human Eyes Treated with Brimonidine and Dorzolamide, Alone and in Combination

Archives of Ophthalmology

Volumn 122, Issue 2, 2004, Pages 190-193

  Tsukamoto, Hidetoshi ^a   Larsson, Lill Inger ^a  

^a UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BRIMONIDINE; DORZOLAMIDE; PLACEBO;

ADULT; AQUEOUS HUMOR FLOW; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG POTENTIATION; FEMALE; FLUORESCENCE; HUMAN; INTRAOCULAR PRESSURE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; TONOMETRY;

ADMINISTRATION, TOPICAL; ADULT; ANTIHYPERTENSIVE AGENTS; AQUEOUS HUMOR; CORNEA; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN; FLUOROPHOTOMETRY; HUMANS; INTRAOCULAR PRESSURE; MALE; MANOMETRY; MIDDLE AGED; OPHTHALMIC SOLUTIONS; QUINOXALINES; SULFONAMIDES; THIOPHENES;

EID: 0842305649     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: 10.1001/archopht.122.2.190     Document Type: Article

References (34)

1. Greenfield DS, Liebmann JM, Ritch R. Brimonidine: a new α2-receptor agonist for glaucoma treatment. J Glaucoma. 1997;6:250-258.
2. Schuman JS, Horwitz B, Choplin NT, et al. Chronic Brimonidine Study Group. A 1-year study of brimonidine twice daily in glaucoma and ocular hypertension: a controlled, randomized, multicenter clinical trial. Arch Ophthalmol. 1997;115:847-852.
3. Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology. 1997;104:131-136.
4. Serle JB, Brimonidine Study Group III. A comparison of the safety and efficacy of twice daily brimonidine 0.2% versus betaxolol 0.25% in subjects with elevated intraocular pressure. Surv Ophthalmol. 1996;41(suppl 1):S39-S47.
5. Schuman JS. Clinical experience with brimonidine 0.2% and timolol 0.5% in glaucoma and ocular hypertension. Surv Ophthalmol. 1996;41(suppl 1):S27-S37.
6. Walters TR. Development and use of brimonidine in treating acute and chronic elevations of intraocular pressure: a review of safety, efficacy, dose response, and dosing studies. Surv Ophthalmol. 1996;41(suppl 1):S19-S26.
7. Burke J, Schwartz M. Preclinical evaluation of brimonidine. Surv Ophthalmol. 1996;41(suppl 1):S9-S18.
8. Schadlu R, Maus TL, Nau CB, Brubaker RF. Comparison of the efficacy of apraclonidine and brimonidine as aqueous suppressants in humans. Arch Ophthalmol. 1998;116:1441-1444.
9. Ogodigben M, Chu TC, Potter DE. Alpha-2 adrenoreceptor mediated changes in aqueous dynamics: effect of pertussis toxin. Exp Eye Res. 1994;58:729-736.
10. Gabelt BT, Robinson JC, Hubbard WC, et al. Apraclonidine and brimonidine effects on anterior ocular and cardiovascular physiology in normal and sympathectomized monkeys. Exp Eye Res. 1994;59:633-644.
11. Toris CB, Gleason ML, Camras CB, Yablonski ME. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113:1514-1517.
12. Centofanti M, Manni G, Gregori D, Cocco F, Lorenzano D, Bucci MG. Comparative acute effects of brimonidine 0.2% versus dorzolamide 2% combined with β-blockers in glaucoma. Graefes Arch Clin Exp Ophthalmol. 2000;238:302-305.
13. Lee DA, Gornbein J, Abrams C, Glaucoma Trial Study Group. The effectiveness and safety of brimonidine as mono-, combination, or replacement therapy for patients with primary open-angle glaucoma or ocular hypertension: a post hoc analysis of an open-label community trial. J Ocul Pharmacol Ther. 2000;16:3-18.
14. Stewart WC, Sharpe ED, Day DG, et al. Comparison of the efficacy and safety of latanoprost 0.005% compared to brimonidine 0.2% or dorzolamide 2% when added to a topical 3-adrenergic blocker in patients with primary open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2000;16:251-259.
15. Strahlman ER, Vogel R, Tipping R, Clineschmidt CM, Dorzolamide Additivity Study Group. The use of dorzolamide and pilocarpine as adjunctive therapy to timolol in patients with elevated intraocular pressure. Ophthalmology. 1996;103:1283-1293.
16. Serle JB, Podos SM, Lee P-Y, Camras CB, Severin CH. Effect of α2-adrenergic agonists on uveoscleral outflow in rabbits. Invest Ophthalmol Vis Sci. 1991;32 (suppl):867.
17. Maus TL, Larsson LI, McLaren JW, Brubaker RF. Comparison of dorzolamide and acetazolamide as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:45-49.
18. Wayman L, Larsson LI, Maus T, Aim A, Brubaker RF. Comparison of dorzolamide and timolol as suppressors of aqueous humor flow in humans. Arch Ophthalmol. 1997;115:1368-1371.
19. Wayman L, Larsson LI, Maus T, Brubaker RF. Additive effect of dorzolamide on aqueous humor flow in patients receiving long-term treatment with timolol. Arch Ophthalmol. 1998;116:1438-1440.
20. Larsson LI, Alm A. Aqueous humor flow in human eyes treated with dorzolamide and different doses of acetazolamide. Arch Ophthalmol. 1998;116:19-24.
21. Vanlandingham BD, Brubaker RF. Combined effect of dorzolamide and latanoprost on the rate of aqueous humor flow. Am J Ophthalmol. 1998;126:191-196.
22. Vanlandingham BD, Maus TL, Brubaker RF. The effect of dorzolamide on aqueous humor dynamics in normal human subjects during sleep. Ophthalmology. 1998;105:1537-1540.
23. Ingrato CJ, Brubaker RF. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol. 1999;128:292-296.
24. Larsson LI. Aqueous humor flow in normal human eyes treated with brimonidine and timolol, alone and in combination. Arch Ophthalmol. 2001;119:492-495.
25. Boyle JE, Ghosh K, Gieser DK, Adamsons IA, Dorzolamide-Timolol Study Group. A randomized trial comparing the dorzolamide-timolol combination given twice daily to monotherapy with timolol and dorzolamide. Ophthalmology. 1998;105:1945-1951.
26. Clineschmidt CM, Williams RD, Snyder E, Adamsons A, Dorzolamide-Timolol Combination Study Group. A randomized trial in patients inadequately controlled with timolol alone comparing the dorzolamide-timolol combination to monotherapy with timolol of dorzolamide. Ophthalmology. 1998;105:1952-1959.
27. Adamsons IA, Polis A, Ostrov CS, Boyle JE, Dorzolamide Safety Study Group. Two-year safety study of dorzolamide as monotherapy and with timolol and pilocarpine. J Glaucoma. 1998;7:395-401.
28. Le HH, Chang MR, Cheng Q, Lee DA, Hartenbaum D. The effectiveness and safety of dorzolamide 2% in addition to multiple topical antiglaucoma medications. J Ocul Pharmacol Ther. 1999;15:305-312.
29. Emmerich KH. Comparison of latanoprost monotherapy to dorzolamide combined with timolol in patients with glaucoma and ocular hypertension: a 3-month randomised study. Graefes Arch Clin Exp Ophthalmol. 2000;238:19-23.
30. Brubaker RF. Measurement of aqueous flow by fluorophotometry. In: Ritch R, Shields MB, Krupin T, eds. The Glaucomas. Vol 1. St Louis, Mo: CV Mosby Co; 1989:337-344.
31. Brubaker RF. Flow of aqueous humor in humans: the Friedenwald Lecture. Invest Ophthalmol Vis Sci. 1991;32:3145-3166.
32. Dixon WJ, Massey JF Jr. Introduction to Statistical Analysis. New York, NY: McGraw-Hill Book Co; 1969:516.
33. Maus TL, Nau C, Brubaker RF. Comparison of the early effects of brimonidine and apraclonidine as topical ocular hypotensive agents. Arch Ophthalmol. 1999;117:586-591.
34. Brubaker RF, Ingram CJ, Schoff EO, Nau CB. Comparison of the efficacy of betaxolol-brinzolamide and timolol-dorzolamide as suppressors of aqueous humor flow in human subjects. Ophthalmology. 2000;107:283-287.